Interní Med. 2012; 14(4): 143-146

Incretins - intestinal hormones affecting not only insulin secretion

MUDr.Marcela Szabó
Městská nemocnice Neratovice

The cells of the small intestine produce two hormones belonging to the incretin system – glucagon-like peptide-1 (GLP-1) and gastric

inhibitory polypeptide (GIP). Their secretion increases mainly postprandially. Reduced postprandial increase in GLP-1 and reduced sensitivity

of pancreatic beta cells to GLP-1 and GIP effects have been demonstrated in type 2 diabetics compared to non-diabetic individuals.

In type 2 diabetes mellitus, the enzyme dipeptidyl peptidase-4 (DPP-4) known to rapidly degrade incretins also contributes to the

insufficient effect of incretins even with high glucose levels. Incretins result not only in increased insulin secretion from the secretory

granules of pancreatic beta cells when blood glucose is increased, but also in postprandial suppression of glucagon secretion. They also

possess numerous other „non-glycemic“ effects. Some of them slow down gastric emptying and, through their central effect, accelerate

the sensation of saturation and reduce the feeling of hunger in the central nervous system, reduce systolic blood pressure and, in experiments,

interfere with degenerative processes in Alzheimer‘s disease or osteopenia.

pressure.

Keywords: glucagon-like peptide-1, gastric inhibitory polypeptide, non-glycemic effects, weight reduction, reduction in systolic blood

Published: April 23, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Szabó M. Incretins - intestinal hormones affecting not only insulin secretion. Interní Med. 2012;14(4):143-146.
Download citation

References

  1. McGill JB. Liraglutide: effects beyond glycaemic control in diabetes treatment. Int J Clin Pract 2010; 64(Suppl 167): 28-34. Go to original source... Go to PubMed...
  2. DeFronzo RA, Okerson T, Viswanathan P, et al. Effects of exenatide versus sitagliptin on postprandial glukose, insulin and glucagon secretion, Bystric emptying and caloric intake: a randomized cross-over study. Curr Med Res Opin 2008; 24: 2943-2952. Go to original source... Go to PubMed...
  3. Buse JB, Rosenstock J, Sesti G, et al for the LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 39-47. Go to original source... Go to PubMed...
  4. Jendle J, Nauck MA, Matthews DR, et al. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab 2009; 11(12): 1163-1172. Go to original source... Go to PubMed...
  5. Pratley R, Nauck M, Bailey T, et al. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patiens with type 2 diabetes: a randomised, paralel-group, open-label trial. Int J Clin Pract 2011; 65: 397-407. Go to original source... Go to PubMed...
  6. Tailor K, Guiney K, Han J, et al. Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years. BMC Endocrine Disorders 2011; 11: 9; http://www.biomedcentral.com/1472-6823/11/9. Go to original source... Go to PubMed...
  7. Fonseca V, Madsbad S, Falahati A, et al. Once-daily human GLP-1 analog liraglutide reduces systolic BP-A meta-analysis of 6 clinical trials. Diabetes 2009; 58(Suppl 1): A146-A146.
  8. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 mono): A randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373(9662): 473-481. Go to original source... Go to PubMed...
  9. Marre M, Shaw J, Brändle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009; 26(3): 268-278. Go to original source... Go to PubMed...
  10. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (liraglutide effect and action in diabetes) -2 study. Diabetes Care 2009; 32(1): 84-90. Go to original source... Go to PubMed...
  11. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD5 met+SU): A randomised controlled trial. Diabetologia 2009, 52 (10): 2046-2055. Go to original source... Go to PubMed...
  12. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009; 32(7): 1224-1230. Go to original source... Go to PubMed...
  13. Lonborg J, Vejlstrup N, Kelbak H, et al. Exenatide reduces reperfusion injury in patiens with ST-segment elevation myocardial infarction. Eur Heart J. 2011; 14(doi: 10.1093/eurheartj/ehr309).
  14. Davidson MH. Cardiovascular effects of glucagonlike peptide-1 agonists. Am J cardiol. 2011; 108(Suppl 3): 33B-41B. Go to original source... Go to PubMed...
  15. McClean PL, Parthsarathy V, Faivre E, Holscher C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimers disease. The Journal of Neuroscience 2011; 31(17): 6587-6594. Go to original source... Go to PubMed...
  16. Holscher C. Diabetes as a risk factor for Alzheimers disease: insulin signaling impairment in the brain as an alternative model of Alzheimer disease. Biochem Soc Trans. 2011; 39: 891-897. Go to original source... Go to PubMed...
  17. Nuche-Berenguer B, Lozano D, Gutierrez-Rojas I, et al. GLP1 and exendin-4 can reverse hyperlipidic-related osteopenia. J Endocrinol. 2011; 209(2): 203-210. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.